Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 7/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.40 |
| ▸ | RRM1 | P23921 | 6/20 | 0.40 |
| ▸ | RRM2B | Q7LG56 | 6/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13889067 | 0.95 | PPARG (0.39) | PPARGIDH1ALPLCHRM2CHRM1 | |
| SCHEMBL4517562 | 0.84 | WDR5 (0.50) | ALPL | |
| SCHEMBL4510480 | 0.79 | ALPL (0.48) | ALPL | |
| SCHEMBL4518235 | 0.79 | ALDH1A1 (0.44) | ALPLCHRM2CHRM1RRM1RRM2B | |
| SCHEMBL4512653 | 0.79 | MMP7 (0.46) | ALPL | |
| SCHEMBL4515854 | 0.78 | CHRM2 (0.40) | CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL4516340 | 0.76 | KMT2A (0.48) | ALPLCHRM2CHRM1RRM1RRM2B | |
| SCHEMBL4507378 | 0.76 | MMP13 (0.47) | — | |
| SCHEMBL4515213 | 0.75 | NR3C1 (0.55) | — | |
| SCHEMBL3019250 | 0.73 | ALPL (0.55) | PPARGIDH1ALPLCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| EP-1807391-A1 | NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | AstraZeneca AB (SE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006046916-A1 | NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | PPARG 122/4885IDH1 3656/4885ALPL 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.